AZ’s Brilinta reduced rate of stroke and death in high-risk subgroup
New analysis of prespecified subgroup comes from phase III THALES trial
Read More
Tag: THALES
AZ unveils detailed data from THALES trial
The results show a 17% cut in the risk of subsequent stroke in patients taking Brilinta and aspirin
Read More
US priority review for AZ’ Brilinta/aspirin combination
Brilinta/aspirin combo could be the first US-approved dual antiplatelet therapy to cut risk of second stroke
Read More
- HUTCHMED begins global trial of novel attc therapy hmpl‑a580 in solid tumours
- Theolytics awarded €8 million Horizon Europe grant to fund ovarian cancer study
- AI system aims to uncover Alzheimer’s earlier and take on diagnostic delays
- Quell launches chill phase 1/2 trial for novel cartreg therapy
- Bioxytran reports positive phase 1b/2a results for antiviral ProLectin‑M
